<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03954366</url>
  </required_header>
  <id_info>
    <org_study_id>CO-338-095</org_study_id>
    <nct_id>NCT03954366</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives</brief_title>
  <official_title>A Phase 1, Open-label, Drug-drug-interaction Study to Determine the Effect of Rucaparib on the Pharmacokinetics of Oral Rosuvastatin (Arm A) and Oral Contraceptives (Ethinylestradiol and Levonorgestrel) (Arm B) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clovis Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clovis Oncology, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the drug-drug interactions (DDIs) between rucaparib and oral
      rosuvastatin (Arm A), and between rucaparib and oral ethinylestradiol and levonorgestrel (Arm
      B), with rucaparib as a perpetrator.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open-label, drug-drug-interaction (DDI) study in patients with advanced
      solid tumor. In Part I, the effects of rucaparib (600 mg twice daily [BID]) on the PK of oral
      rosuvastatin (Arm A) and the combined oral contraceptives (ethinylestradiol and
      levonorgestrel; Arm B) will be assessed.

      Part I: patients will receive single oral doses of rosuvastatin or oral contraceptives
      (according to assigned arm) on Day 1 and Day 19. Continuous treatment with rucaparib at 600
      mg BID will commence on Day 5 and continue until the end of Part I (Day 23).

      Part II (optional): treatment with rucaparib in 28-day cycles may continue (at the discretion
      of the Investigator) until progression of disease, unacceptable toxicity, or other reason for
      discontinuation.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 8, 2019</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Actual">December 6, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters for oral rosuvastatin, ethinylestradiol and levonorgestrel without and with rucaparib treatment.</measure>
    <time_frame>Day 1 to Day 23</time_frame>
    <description>Maximum plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters for oral rosuvastatin, ethinylestradiol and levonorgestrel without and with rucaparib treatment.</measure>
    <time_frame>Day 1 to Day 23</time_frame>
    <description>Area under the concentration-time curve (AUC) from time zero up to the last time point with a quantifiable concentration (AUC0-last)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters for oral rosuvastatin, ethinylestradiol and levonorgestrel without and with rucaparib treatment.</measure>
    <time_frame>Day 1 to Day 23</time_frame>
    <description>AUC up to time infinity, with extrapolation of the terminal phase (AUC0-inf)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters for oral rosuvastatin, ethinylestradiol and levonorgestrel without and with rucaparib treatment.</measure>
    <time_frame>Day 1 to Day 23</time_frame>
    <description>Terminal half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters for oral rosuvastatin, ethinylestradiol and levonorgestrel without and with rucaparib treatment.</measure>
    <time_frame>Day 1 to Day 23</time_frame>
    <description>Time to occurrence of Cmax (tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters for oral rosuvastatin, ethinylestradiol and levonorgestrel without and with rucaparib treatment.</measure>
    <time_frame>Day 1 to Day 23</time_frame>
    <description>Apparent total clearance of drug after oral administration (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters for oral rosuvastatin, ethinylestradiol and levonorgestrel without and with rucaparib treatment.</measure>
    <time_frame>Day 1 to Day 23</time_frame>
    <description>Apparent volume of distribution during terminal phase (Vz/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The following secondary PK parameter will be calculated for rucaparib.</measure>
    <time_frame>Day 1 to Day 23</time_frame>
    <description>Trough plasma concentration (Cmin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events [Safety and Tolerability]</measure>
    <time_frame>From Day 1 to last patient visit in Part II (approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinical laboratory abnormalities [Safety and Tolerability]</measure>
    <time_frame>From Day 1 to last patient visit in Part II (approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of dose modifications [Safety and Tolerability]</measure>
    <time_frame>From Day 1 to last patient visit in Part II (approximately 2 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A - rucaparib and oral rosuvastatin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - rucaparib and oral contraceptives</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rucaparib</intervention_name>
    <description>Rucaparib 600 mg BID commencing on Day 5 until Day 23.</description>
    <arm_group_label>Arm A - rucaparib and oral rosuvastatin</arm_group_label>
    <arm_group_label>Arm B - rucaparib and oral contraceptives</arm_group_label>
    <other_name>Rubraca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Single dose of 20mg oral rosuvastatin on Day 1 and Day 19 only.</description>
    <arm_group_label>Arm A - rucaparib and oral rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Contraceptives</intervention_name>
    <description>Single dose of combined oral contraceptive (30 μg ethinylestradiol and 150 μg levonorgestrel) on Day 1 and Day 19 only.</description>
    <arm_group_label>Arm B - rucaparib and oral contraceptives</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (All patients):

          -  Willing to sign the ICF and to comply with the study restrictions

          -  Body mass index (BMI) 18.0 to 35.0 kg/m2

          -  Histologically or cytologically confirmed advanced solid tumor

          -  Patients who, in the opinion of the Investigator, could potentially benefit from
             treatment with rucaparib

          -  ECOG performance status less than or equal to 1

          -  Adequate organ function

        Inclusion Criteria (Arm A):

        - Male or female patients ≥ 18 years of age

        Inclusion Criteria (Arm B):

        - Female patients ≥ 18 years of age

        Exclusion Criteria (All patients):

          -  Specific cancer treatments within 14 days prior to Day 1

          -  Arterial or venous thrombi (including cerebrovascular accident), myocardial
             infarction, admission for unstable angina, acute coronary syndrome, cardiac
             angioplasty, stenting, or poorly controlled hypertension within the last 3 months
             prior to screening

          -  Pre-existing duodenal stent, recent or existing bowel obstruction

          -  Untreated or symptomatic central nervous system (CNS) metastases. Patients with
             treated asymptomatic CNS metastases are eligible

          -  Known HIV or AIDS-related illness, acute or history of chronic hepatitis B or C

          -  Female patients who are pregnant or breastfeeding

          -  Participation in another investigational drug trial within 30 days prior to Day 1 or
             exposure to more than 3 new investigational agents within 12 months prior to Day 1

          -  Presence of active infection requiring antibiotics

          -  Active second malignancy

          -  History of drug abuse (including alcohol)

        Exclusion Criteria (Arm A):

          -  Current use of rosuvastatin or any other statin

          -  History of hypersensitivity to rosuvastatin

          -  Current, or history of, clinically significant myopathy

        Exclusion Criteria (Arm B):

          -  Current use of any 1 of the contraceptive drugs or previous contraceptive implants or
             depot injections, which may still be clinically effective

          -  History of hypersensitivity to ethinylestradiol or levonorgestrel
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Both male and female patients are eligible for Arm A. Female patients only are eligible for Arm B.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PRA Magyarország Fázis I-es Klinikai Farmakológiai Vizsgálóhely FMC Dialízis Központ, II. em.</name>
      <address>
        <city>Budapest</city>
        <zip>1076</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej</name>
      <address>
        <city>Biała Podlaska</city>
        <zip>21-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioVirtus Centrum Medyczne</name>
      <address>
        <city>Józefów</city>
        <zip>05-410</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ujastek Sp. z o.o. Centrum medyczne</name>
      <address>
        <city>Kraków</city>
        <zip>31-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Polonia Sp. z o.o.</name>
      <address>
        <city>Poznań</city>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zdrowie Kobiety Centrum Leczniczo-Rehabilitacyjne i Medycyny Pracy ATTIS Sp. z o.o., Zakład Onkologii Kobiecej</name>
      <address>
        <city>Warszawa</city>
        <zip>01-401</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Clinical Research s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <zip>831 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2019</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rucaparib</keyword>
  <keyword>CO-338</keyword>
  <keyword>Clovis</keyword>
  <keyword>Clovis Oncology</keyword>
  <keyword>PARP Inhibitor</keyword>
  <keyword>Drug-drug Interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rucaparib</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

